RIPE-KG · Version 1.1.0 · Resource
ripekg:publication-details/RIPEA10E0E50BEC9CF233
https://w3id.org/ripe/ripe-kg/publication-details/RIPEA10E0E50BEC9CF233
| Subject | Predicate | Object |
|---|---|---|
ripekg:evaluation/RIPEA10E0E50BEC9CF233 |
prov:used |
ripekg:publication-details/RIPEA10E0E50BEC9CF233Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial |
ripekg:publication-details/RIPEA10E0E50BEC9CF233Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial |
prism:eIssn |
1756-1833 |
ripekg:publication-details/RIPEA10E0E50BEC9CF233Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial |
prism:publicationDate |
2025-09-11 |
ripekg:publication-details/RIPEA10E0E50BEC9CF233Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial |
prism:publicationName |
BMJ |
ripekg:publication-details/RIPEA10E0E50BEC9CF233Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial |
dcterms:publisher |
ripekg:publisher/RIPEP9377BEC70BC5BE0FBMJ |
ripekg:publication-details/RIPEA10E0E50BEC9CF233Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial |
dcterms:title |
Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial |
ripekg:publication-details/RIPEA10E0E50BEC9CF233Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial |
rdf:type |
http://purl.org/spar/fabio/BibliographicMetadata |
ripekg:publication-details/RIPEA10E0E50BEC9CF233Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial |
rdf:type |
rdfs:Resource |
ripekg:publication-details/RIPEA10E0E50BEC9CF233Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial |
rdf:type |
owl:Thing |
ripekg:publication-details/RIPEA10E0E50BEC9CF233Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial |
rdf:type |
ripe:IntegrityAssessmentEvidenceIntegrity assessment evidence |
ripekg:publication-details/RIPEA10E0E50BEC9CF233Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial |
rdf:type |
ripe:PublicationDetailsPublication details |
ripekg:publication-details/RIPEA10E0E50BEC9CF233Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial |
rdf:type |
tido:Evidence |
ripekg:publication-details/RIPEA10E0E50BEC9CF233Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA10E0E50BEC9CF233 |
ripekg:publication-details/RIPEA10E0E50BEC9CF233Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA10E0E50BEC9CF233 |
ripekg:publication-details/RIPEA10E0E50BEC9CF233Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial |
ripe:concerns |
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial |
ripekg:publication-details/RIPEA10E0E50BEC9CF233Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial |
ripe:concerns |
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies |
ripekg:publication-details/RIPEA10E0E50BEC9CF233Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA10E0E50BEC9CF233-human-1-1 |
ripekg:publication-details/RIPEA10E0E50BEC9CF233Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA10E0E50BEC9CF233-inspectai-1-1 |